 - Patients will be enrolled on this trial after resection of hepatic metastases combined with FOLFIRI or FOLFOX - Bevacizumab, or XELOX; patients may have received a maximum of 12 cycles of FOLFIRI or FOLFOX - Bevacizumab, or XELOX, which includes chemotherapy prior to and post hepatic resection 